78946-25-5

Basic information

• Product Name: methyl 3-bromo-4-(bromomethyl)benzoate
• Synonyms: methyl 3-bromo-4-(bromomethyl)benzoate;Benzoic acid, 3-bromo-4-(bromomethyl)-, methyl ester (Related Reference);3-Bromo-4-bromomethyl-benzoic acid methyl ester;CFJQBNFFHMBNKQ-UHFFFAOYSA-N
• CAS NO: 78946-25-5
• Molecular Formula: C₉H₈Br₂O₂
• Molecular Weight: 307.96662
• Mol File: 78946-25-5.mol
• Article Data: 25

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 3-bromo-4-(bromomethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-bromo-4-(bromomethyl)benzoate(78946-25-5)
• EPA Substance Registry System: methyl 3-bromo-4-(bromomethyl)benzoate(78946-25-5)

Safety Data

• Hazardous Substances Data: 78946-25-5(Hazardous Substances Data)

Upstream product

• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 7697-26-9 3-bromo-4-methylbenzoic acid 

Downstream Products

• 1069114-89-1 methyl 3-bromo-4-(cyanomethyl)benzoate 
• 90484-53-0 3-bromo-4-formyl-benzoic acid methyl ester 
• 1224340-64-0 dimethyl 4,4'-(ethane-1,2-diyl)bis(3-bromobenzoate) 
• 1221343-14-1 1-(hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)carboxylic acid 
• 1080573-21-2 4-acetoxymethyl-3-bromobenzoic acid methyl ester 
• 90326-62-8 3-bromo-4-hydroxymethylbenzoic acid methyl ester 
• 1069114-91-5 methyl 3-bromo-4-[(methoxycarbonyl)methyl]benzoate 

Relevant articles and documents

Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is becoming the most predominant burden of chronic liver disease worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, can develop into cirrhosis and hepatocellular cancer. Unfortunately, current options for therapeutic treatment of NASH are very limited. Among multiple pathways in NASH, farnesoid X receptor (FXR), a nuclear bile acid receptor, is well-recognized as an important effective target. Here we report the synthesis and characterization of compound HEC96719 a novel tricyclic FXR agonist based on a prior high-affinity nonsteroidal molecule GW4064. HEC96719 exhibits excellent potency superior to GW4064 and obeticholic acid in in vitro and in vivo assays of FXR activation. It also shows higher FXR selectivity and more favorable tissue distribution dominantly in liver and intestine. Preclinical data on pharmacokinetic properties, efficacy, and safety profiles overall indicate that HEC96719 is a promising drug candidate for NASH treatment.

Annulated bacteriochlorins for near-infrared photophysical studies

Molecules with strong absorption in the near-infrared (NIR) spectral region are of interest for a variety of applications in the photosciences. Nature's NIR absorbers are bacteriochlorophylls, which contain a tetrahydroporphyrin chromophore accentuated by

A Four-Step Synthesis of (±)-γ-Lycorane via Pd0-Catalyzed Double C(sp2)-H/C(sp3)-H Arylation

An expedient synthesis of lycorine alkaloids is reported using a palladium(0)-catalyzed double C-X/C-H arylation as the key step. The selectivity of this reaction was controlled through the judicious choice of the two halogen atoms, and its generality was